{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:32:52Z","timestamp":1791351172804,"version":"4.3.1"},"reference-count":108,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["cell.com","bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.tips.2014.09.007","type":"journal-article","created":{"date-parts":[[2014,10,10]],"date-time":"2014-10-10T16:33:16Z","timestamp":1412958796000},"page":"604-620","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":172,"title":["Advances in kinase targeting: current clinical use and clinical trials"],"prefix":"10.1016","volume":"35","author":[{"given":"Mathias","family":"Rask-Andersen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doriano","family":"Fabbro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helgi B.","family":"Schi\u00f6th","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2014.09.007_bib0005","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1146\/annurev-pharmtox-011613-135943","article-title":"Evaluation of the targets for drugs in clinical trials suggests major shift in molecular class and indication","volume":"54","author":"Rask-Andersen","year":"2014","journal-title":"Annu. Rev. Tox. Pharm."},{"key":"10.1016\/j.tips.2014.09.007_bib0010","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.tips.2014.09.007_bib0015","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.cellsig.2011.05.004","article-title":"Akt signalling in health and disease","volume":"23","author":"Hers","year":"2011","journal-title":"Cell. Signal."},{"key":"10.1016\/j.tips.2014.09.007_bib0020","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1161\/CIRCRESAHA.110.217117","article-title":"Activation of protein kinase C isoforms and its impact on diabetic complications","volume":"106","author":"Geraldes","year":"2010","journal-title":"Circ. Res."},{"key":"10.1016\/j.tips.2014.09.007_bib0025","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.bbadis.2009.12.009","article-title":"Pathological roles of MAPK signaling pathways in human diseases","volume":"1802","author":"Kim","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.tips.2014.09.007_bib0030","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrn3068","article-title":"Fighting neurodegeneration with rapamycin: mechanistic insights","volume":"12","author":"Bove","year":"2011","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.tips.2014.09.007_bib0035","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of rheumatoid arthritis","volume":"365","author":"McInnes","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2014.09.007_bib0040","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrd3478","article-title":"Trends in the exploitation of novel drug targets","volume":"10","author":"Rask-Andersen","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tips.2014.09.007_bib0045","doi-asserted-by":"crossref","first-page":"D1035","DOI":"10.1093\/nar\/gkq1126","article-title":"DrugBank 3.0: a comprehensive resource for \u2018omics\u2019 research on drugs","volume":"39","author":"Knox","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.tips.2014.09.007_bib0525","doi-asserted-by":"crossref","first-page":"D43","DOI":"10.1093\/nar\/gks1068","article-title":"Update on activities at the Universal Protein Resource (UniProt) in 2013","volume":"41","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.tips.2014.09.007_bib0050","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.1075762","article-title":"The protein kinase complement of the human genome","volume":"298","author":"Manning","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.tips.2014.09.007_bib0530","doi-asserted-by":"crossref","first-page":"D71","DOI":"10.1093\/nar\/gkr981","article-title":"Reorganizing the protein space at the Universal Protein Resource (UniProt)","volume":"40","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.tips.2014.09.007_bib0055","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.tcb.2006.07.003","article-title":"Emerging roles of pseudokinases","volume":"16","author":"Boudeau","year":"2006","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.tips.2014.09.007_bib0060","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.cell.2008.04.005","article-title":"Rethinking pseudokinases","volume":"133","author":"Kannan","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.tips.2014.09.007_bib0065","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1038\/sj.onc.1203957","article-title":"The protein tyrosine kinase family of the human genome","volume":"19","author":"Robinson","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.tips.2014.09.007_bib0070","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrd839","article-title":"Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug","volume":"1","author":"Capdeville","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tips.2014.09.007_bib0075","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/nrc2559","article-title":"Targeting cancer with small molecule kinase inhibitors","volume":"9","author":"Zhang","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.tips.2014.09.007_bib0080","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nbt1068","article-title":"A small molecule\u2013kinase interaction map for clinical kinase inhibitors","volume":"23","author":"Fabian","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.tips.2014.09.007_bib0085","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nbt1358","article-title":"A quantitative analysis of kinase inhibitor selectivity","volume":"26","author":"Karaman","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.tips.2014.09.007_bib0090","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00262-011-1077-4","article-title":"Immunotherapy with MVA-BN(R)-HER2 induces HER-2-specific Th1 immunity and alters the intratumoral balance of effector and regulatory T cells","volume":"61","author":"Mandl","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.tips.2014.09.007_bib0095","doi-asserted-by":"crossref","first-page":"5937","DOI":"10.1158\/1078-0432.CCR-08-3282","article-title":"A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2\/neu","volume":"15","author":"Peethambaram","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tips.2014.09.007_bib0100","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/PPO.0b013e31829d74b4","article-title":"A new age for vaccine therapy in renal cell carcinoma","volume":"19","author":"Pal","year":"2013","journal-title":"Cancer J."},{"key":"10.1016\/j.tips.2014.09.007_bib0105","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/PPO.0b013e318233e6b4","article-title":"Lung cancer vaccines","volume":"17","author":"Kelly","year":"2011","journal-title":"Cancer J."},{"key":"10.1016\/j.tips.2014.09.007_bib0110","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00262-012-1319-0","article-title":"Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma","volume":"62","author":"Phuphanich","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.tips.2014.09.007_bib0115","doi-asserted-by":"crossref","DOI":"10.1007\/s00262-014-1582-3","article-title":"AE37 peptide vaccination in prostate cancer: identification of biomarkers in the context of prognosis and prediction","author":"Perez","year":"2014","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.tips.2014.09.007_bib0120","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1158\/2159-8290.CD-12-0429","article-title":"First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement","volume":"3","author":"Tabernero","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.tips.2014.09.007_bib0125","doi-asserted-by":"crossref","first-page":"76","DOI":"10.5414\/CPP50076","article-title":"Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors","volume":"50","author":"Strumberg","year":"2012","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.tips.2014.09.007_bib0130","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1158\/1078-0432.CCR-12-0055","article-title":"Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling","volume":"18","author":"Qian","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tips.2014.09.007_bib0135","doi-asserted-by":"crossref","first-page":"5497","DOI":"10.1038\/onc.2008.245","article-title":"PI3K pathway alterations in cancer: variations on a theme","volume":"27","author":"Yuan","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.tips.2014.09.007_bib0140","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.2174\/092986707781696636","article-title":"Protein kinases as small molecule inhibitor targets in inflammation","volume":"14","author":"Gaestel","year":"2007","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.tips.2014.09.007_bib0145","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2165\/11633120-000000000-00000","article-title":"Pharmacokinetics, safety, and tolerability of GLPG0259, a mitogen-activated protein kinase-activated protein kinase 5 (MAPKAPK5) inhibitor, given as single and multiple doses to healthy male subjects","volume":"12","author":"Namour","year":"2012","journal-title":"Drugs R D"},{"key":"10.1016\/j.tips.2014.09.007_bib0150","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1136\/annrheumdis-2012-202221","article-title":"Oral administration of GLPG0259, an inhibitor of MAPKAPK5, a new target for the treatment of rheumatoid arthritis: a phase II, randomised, double-blind, placebo-controlled, multicentre trial","volume":"72","author":"Westhovens","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.tips.2014.09.007_bib0155","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3899\/jrheum.120923","article-title":"Effects of fostamatinib (R788), an oral spleen tyrosine kinase inhibitor, on health-related quality of life in patients with active rheumatoid arthritis: analyses of patient-reported outcomes from a randomized, double-blind, placebo-controlled trial","volume":"40","author":"Weinblatt","year":"2013","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.tips.2014.09.007_bib0160","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrc2694","article-title":"Signal integration by JNK and p38 MAPK pathways in cancer development","volume":"9","author":"Wagner","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.tips.2014.09.007_bib0165","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nrd1177","article-title":"p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases","volume":"2","author":"Kumar","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tips.2014.09.007_bib0170","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1126\/science.7914033","article-title":"A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells","volume":"265","author":"Han","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.tips.2014.09.007_bib0175","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/art.24264","article-title":"Inhibition of p38: has the fat lady sung?","volume":"60","author":"Genovese","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.tips.2014.09.007_bib0180","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1517\/17460441.2010.504203","article-title":"Targeting kinases for the treatment of inflammatory diseases","volume":"5","author":"Muller","year":"2010","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.tips.2014.09.007_bib0185","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1177\/0091270010397050","article-title":"An oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease","volume":"52","author":"Lomas","year":"2012","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.tips.2014.09.007_bib0190","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jcmg.2012.02.016","article-title":"Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis","volume":"5","author":"Elkhawad","year":"2012","journal-title":"JACC Cardiovasc. Imaging"},{"key":"10.1016\/j.tips.2014.09.007_bib0195","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/j.1532-2149.2012.00256.x","article-title":"Analgesic efficacy and safety of the novel p38 MAP kinase inhibitor, losmapimod, in patients with neuropathic pain following peripheral nerve injury: a double-blind, placebo-controlled study","volume":"17","author":"Ostenfeld","year":"2013","journal-title":"Eur. J. Pain"},{"key":"10.1016\/j.tips.2014.09.007_bib0200","doi-asserted-by":"crossref","first-page":"e7258","DOI":"10.1371\/journal.pone.0007258","article-title":"Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT","volume":"4","author":"Dubreuil","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.tips.2014.09.007_bib0205","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.critrevonc.2013.12.011","article-title":"Masitinib (AB1010), from canine tumor model to human clinical development: where we are?","volume":"91","author":"Marech","year":"2014","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.tips.2014.09.007_bib0210","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jbspin.2012.08.013","article-title":"Mast cells and inflammation","volume":"80","author":"Frenzel","year":"2013","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.tips.2014.09.007_bib0215","doi-asserted-by":"crossref","first-page":"R95","DOI":"10.1186\/ar2740","article-title":"Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study","volume":"11","author":"Tebib","year":"2009","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.tips.2014.09.007_bib0220","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1111\/j.1398-9995.2009.02122.x","article-title":"Masitinib, a c-kit\/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics","volume":"64","author":"Humbert","year":"2009","journal-title":"Allergy"},{"key":"10.1016\/j.tips.2014.09.007_bib0225","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1471-2377-12-36","article-title":"Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study","volume":"12","author":"Vermersch","year":"2012","journal-title":"BMC Neurol."},{"key":"10.1016\/j.tips.2014.09.007_bib0230","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/alzrt75","article-title":"Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial","volume":"3","author":"Piette","year":"2011","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.tips.2014.09.007_bib0235","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.drudis.2014.03.028","article-title":"Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis","volume":"19","author":"Whang","year":"2014","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.tips.2014.09.007_bib0240","doi-asserted-by":"crossref","first-page":"D109","DOI":"10.1093\/nar\/gkr988","article-title":"KEGG for integration and interpretation of large-scale molecular data sets","volume":"40","author":"Kanehisa","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.tips.2014.09.007_bib0245","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1038\/nrd2999","article-title":"Targeting protein kinases in central nervous system disorders","volume":"8","author":"Chico","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tips.2014.09.007_bib0250","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1111\/j.1471-4159.2007.05194.x","article-title":"The GSK3 hypothesis of Alzheimer's disease","volume":"104","author":"Hooper","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1016\/j.tips.2014.09.007_bib0255","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1365-2990.2006.00795.x","article-title":"Increased level of active GSK-3beta in Alzheimer's disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration","volume":"33","author":"Leroy","year":"2007","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.tips.2014.09.007_bib0260","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1073\/pnas.0308512100","article-title":"Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses","volume":"101","author":"Blalock","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.tips.2014.09.007_bib0265","doi-asserted-by":"crossref","first-page":"6990","DOI":"10.1073\/pnas.0500466102","article-title":"Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo","volume":"102","author":"Noble","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.tips.2014.09.007_bib0270","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1523\/JNEUROSCI.4321-06.2007","article-title":"Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation","volume":"27","author":"Rockenstein","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.tips.2014.09.007_bib0275","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3233\/JAD-2012-120805","article-title":"Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study","volume":"33","author":"del Ser","year":"2013","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.tips.2014.09.007_bib0280","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1042\/bj3320281","article-title":"The extended protein kinase C superfamily","volume":"332","author":"Mellor","year":"1998","journal-title":"Biochem. J."},{"key":"10.1016\/j.tips.2014.09.007_bib0285","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/B978-0-12-394816-8.00008-8","article-title":"Activation of protein kinase C isozymes for the treatment of dementias","volume":"64","author":"Sun","year":"2012","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.tips.2014.09.007_bib0290","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/nar\/28.1.27","article-title":"KEGG: Kyoto encyclopedia of genes and genomes","volume":"28","author":"Kanehisa","year":"2000","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.tips.2014.09.007_bib0295","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/0196-9781(91)90122-6","article-title":"Pretreatment with caerulein protects against memory impairment induced by protein kinase C inhibitors in the rat","volume":"12","author":"Takashima","year":"1991","journal-title":"Peptides"},{"key":"10.1016\/j.tips.2014.09.007_bib0300","doi-asserted-by":"crossref","first-page":"5906","DOI":"10.1523\/JNEUROSCI.20-16-05906.2000","article-title":"A role for the beta isoform of protein kinase C in fear conditioning","volume":"20","author":"Weeber","year":"2000","journal-title":"J. Neurosci."},{"key":"10.1016\/j.tips.2014.09.007_bib0305","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1046\/j.1471-4159.2003.01631.x","article-title":"Estrogen activates protein kinase C in neurons: role in neuroprotection","volume":"84","author":"Cordey","year":"2003","journal-title":"J. Neurochem."},{"key":"10.1016\/j.tips.2014.09.007_bib0310","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1021\/jm020350r","article-title":"New amide-bearing benzolactam-based protein kinase C modulators induce enhanced secretion of the amyloid precursor protein metabolite sAPPalpha","volume":"46","author":"Kozikowski","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2014.09.007_bib0315","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.pneurobio.2012.06.003","article-title":"Kinases and kinase signaling pathways: potential therapeutic targets in Parkinson's disease","volume":"98","author":"Wang","year":"2012","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.tips.2014.09.007_bib0320","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0378-4274(02)00428-9","article-title":"Apoptotic mechanisms and antiapoptotic therapy in the MPTP model of Parkinson's disease","volume":"139","author":"Eberhardt","year":"2003","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.tips.2014.09.007_bib0325","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1212\/01.wnl.0000324506.93877.5e","article-title":"Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease","volume":"71","author":"Wang","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.tips.2014.09.007_bib0330","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1146\/annurev-genom-082410-101440","article-title":"Recent advances in the genetics of Parkinson's disease","volume":"12","author":"Martin","year":"2011","journal-title":"Annu. Rev. Genomics Hum. Genet."},{"key":"10.1016\/j.tips.2014.09.007_bib0335","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nchembio.538","article-title":"Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2","volume":"7","author":"Deng","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.tips.2014.09.007_bib0340","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1021\/cb2002413","article-title":"Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons","volume":"6","author":"Ramsden","year":"2011","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.tips.2014.09.007_bib0345","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.bbrc.2013.10.159","article-title":"Pathogenic Parkinson's disease mutations across the functional domains of LRRK2 alter the autophagic\/lysosomal response to starvation","volume":"441","author":"Manzoni","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.tips.2014.09.007_bib0350","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1016\/j.bbamcr.2013.07.020","article-title":"Inhibition of LRRK2 kinase activity stimulates macroautophagy","volume":"1833","author":"Manzoni","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.tips.2014.09.007_bib0355","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1758-907X-1-14","article-title":"A status report on RNAi therapeutics","volume":"1","author":"Vaishnaw","year":"2010","journal-title":"Silence"},{"key":"10.1016\/j.tips.2014.09.007_bib0360","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.exer.2003.11.016","article-title":"Studies on ocular inflammation and development of a prostaglandin analogue for glaucoma treatment","volume":"78","author":"Stjernschantz","year":"2004","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.tips.2014.09.007_bib0365","first-page":"883","article-title":"An emerging treatment option for glaucoma: Rho kinase inhibitors","volume":"8","author":"Wang","year":"2014","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.tips.2014.09.007_bib0370","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.ajo.2011.04.012","article-title":"Ocular hypotensive effect of the Rho hinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension","volume":"152","author":"Williams","year":"2011","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.tips.2014.09.007_bib0375","article-title":"Clinical development of AR-12286: assessing safety and ocular hypotensive efficacy in patients with elevated intraocular pressure and in normotensive volunteers","author":"van Haarlem","year":"2012","journal-title":"Proc. Eur. Glaucoma Soc. Cong. Copehagen"},{"key":"10.1016\/j.tips.2014.09.007_bib0380","doi-asserted-by":"crossref","first-page":"343560","DOI":"10.1155\/2013\/343560","article-title":"Pathophysiology of diabetic retinopathy","volume":"2013","author":"Tarr","year":"2013","journal-title":"ISRN Ophthalmol."},{"key":"10.1016\/j.tips.2014.09.007_bib0385","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1517\/14728222.2011.553604","article-title":"The role of Raf-1 kinase in diabetic retinopathy","volume":"15","author":"Mohammad","year":"2011","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.tips.2014.09.007_bib0390","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1345\/aph.1E572","article-title":"Ruboxistaurin, a protein kinase C beta inhibitor, as an emerging treatment for diabetes microvascular complications","volume":"39","author":"Joy","year":"2005","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.tips.2014.09.007_bib0395","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1167\/iovs.12-11055","article-title":"The effect of the oral PKC beta inhibitor ruboxistaurin on vision loss in two phase 3 studies","volume":"54","author":"Sheetz","year":"2013","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.tips.2014.09.007_bib0535","series-title":"Regranex (becaplermin) Gel 0.01% October 2008. Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)","author":"US Food and Drug Administration","year":"2008"},{"key":"10.1016\/j.tips.2014.09.007_bib0400","doi-asserted-by":"crossref","DOI":"10.1002\/term.1749","article-title":"Fibrin biomatrix-conjugated platelet-derived growth factor AB accelerates wound healing in severe thermal injury","author":"Mittermayr","year":"2013","journal-title":"J. Tissue Eng. Regen. Med."},{"key":"10.1016\/j.tips.2014.09.007_bib0405","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/PRS.0b013e318217429b","article-title":"Avotermin for scar improvement following scar revision surgery: a randomized, double-blind, within-patient, placebo-controlled, phase II clinical trial","volume":"128","author":"So","year":"2011","journal-title":"Plast Reconstr. Surg."},{"key":"10.1016\/j.tips.2014.09.007_bib0410","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.tins.2009.07.007","article-title":"Critical role of nociceptor plasticity in chronic pain","volume":"32","author":"Reichling","year":"2009","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.tips.2014.09.007_bib0415","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/pme.12088","article-title":"A single-center, randomized, double-blind, active, and placebo-controlled study of KAI-1678, a novel PKC-epsilon inhibitor, in the treatment of acute postoperative orthopedic pain","volume":"14","author":"Moodie","year":"2013","journal-title":"Pain Med."},{"key":"10.1016\/j.tips.2014.09.007_bib0420","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/pme.12058","article-title":"The safety and efficacy of KAI-1678- an inhibitor of epsilon protein kinase C (epsilonPKC)-versus lidocaine and placebo for the treatment of postherpetic neuralgia: a crossover study design","volume":"14","author":"Cousins","year":"2013","journal-title":"Pain Med."},{"key":"10.1016\/j.tips.2014.09.007_bib0425","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/jnc.12093","article-title":"Nerve growth factor-mediated regulation of pain signalling and proposed new intervention strategies in clinical pain management","volume":"124","author":"McKelvey","year":"2013","journal-title":"J. Neurochem."},{"key":"10.1016\/j.tips.2014.09.007_bib0430","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s11926-012-0289-8","article-title":"Control of arthritis pain with anti-nerve-growth factor: risk and benefit","volume":"14","author":"Seidel","year":"2012","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.tips.2014.09.007_bib0540","series-title":"Briefing Book for 12 March 2012 Arthritis Advisory Committee Meeting: JNJ-42160443 (fulranumab)","author":"Janssen Research Advisory Committee","year":"2012"},{"key":"10.1016\/j.tips.2014.09.007_bib0435","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nrd3732","article-title":"Anti-NGF painkillers back on track?","volume":"11","author":"Holmes","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tips.2014.09.007_bib0440","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s11916-011-0183-5","article-title":"Growth factors and neuropathic pain","volume":"15","author":"Ossipov","year":"2011","journal-title":"Curr. Pain Headache Rep."},{"key":"10.1016\/j.tips.2014.09.007_bib0445","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1212\/WNL.60.1.69","article-title":"Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD","volume":"60","author":"Nutt","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.tips.2014.09.007_bib0450","first-page":"165","article-title":"Advances in stent technologies and their effect on clinical efficacy and safety","volume":"7","author":"Nikam","year":"2014","journal-title":"Med. Devices (Auckl.)"},{"key":"10.1016\/j.tips.2014.09.007_bib0455","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.jacc.2013.08.725","article-title":"Stent thrombosis with drug-eluting stents: is the paradigm shifting?","volume":"62","author":"Palmerini","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.tips.2014.09.007_bib0460","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1024\/0301-1526\/a000298","article-title":"Gene therapy for therapeutic angiogenesis in peripheral arterial disease - a systematic review and meta-analysis of randomized, controlled trials","volume":"42","author":"Hammer","year":"2013","journal-title":"Vasa"},{"key":"10.1016\/j.tips.2014.09.007_bib0465","doi-asserted-by":"crossref","first-page":"186215","DOI":"10.1155\/2013\/186215","article-title":"Gene therapy and cell-based therapies for therapeutic angiogenesis in peripheral artery disease","volume":"2013","author":"Shimamura","year":"2013","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.tips.2014.09.007_bib0470","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.cardiores.2006.02.015","article-title":"Epsilon protein kinase C as a potential therapeutic target for the ischemic heart","volume":"70","author":"Inagaki","year":"2006","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.tips.2014.09.007_bib0475","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1161\/CIRCULATIONAHA.107.759167","article-title":"Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction","volume":"117","author":"Bates","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.tips.2014.09.007_bib0480","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1517\/13543784.2013.738666","article-title":"Activin receptor antagonists for cancer-related anemia and bone disease","volume":"22","author":"Fields","year":"2013","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.tips.2014.09.007_bib0485","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.bone.2010.01.370","article-title":"A soluble activin receptor type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys","volume":"46","author":"Lotinun","year":"2010","journal-title":"Bone"},{"key":"10.1016\/j.tips.2014.09.007_bib0490","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.bone.2009.09.018","article-title":"Treatment with a soluble receptor for activin improves bone mass and structure in the axial and appendicular skeleton of female cynomolgus macaques (Macaca fascicularis)","volume":"46","author":"Fajardo","year":"2010","journal-title":"Bone"},{"key":"10.1016\/j.tips.2014.09.007_bib0495","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1359\/jbmr.081208","article-title":"Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women","volume":"24","author":"Ruckle","year":"2009","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.tips.2014.09.007_bib0500","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1159\/000241895","article-title":"Blocking pro-cell-death signal pathways to conserve hearing","volume":"14","author":"Dinh","year":"2009","journal-title":"Audiol. Neurootol."},{"key":"10.1016\/j.tips.2014.09.007_bib0505","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1080\/00016480601110212","article-title":"Intratympanic treatment of acute acoustic trauma with a cell-permeable JNK ligand: a prospective randomized phase I\/II study","volume":"127","author":"Suckfuell","year":"2007","journal-title":"Acta Otolaryngol."},{"key":"10.1016\/j.tips.2014.09.007_bib0510","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/nrd3744","article-title":"Outlook for the next 5 years in drug innovation","volume":"11","author":"Berggren","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tips.2014.09.007_bib0515","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2014.09.007_bib0520","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1480-9222-15-4","article-title":"Next generation sequencing in cancer research and clinical application","volume":"15","author":"Shyr","year":"2013","journal-title":"Biol. Proced. Online"}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614714001606?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614714001606?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,15]],"date-time":"2019-08-15T23:08:36Z","timestamp":1565910516000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165614714001606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":108,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S0165614714001606"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2014.09.007","relation":{},"ISSN":["0165-6147"],"issn-type":[{"value":"0165-6147","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in kinase targeting: current clinical use and clinical trials","name":"articletitle","label":"Article Title"},{"value":"Trends in Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tips.2014.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}